⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
prnewswire.com
JNJ
The Mind Behind the Money: How Brian Spira Spent 30 Years Reshaping Litigation Finance and Legal Operations
globenewswire.com
JNJ
CORRECTION FROM SOURCE: The Nomination Committee's Proposal for New Board Members
accessnewswire.com
GEHC
JNJ
ABT
The Nomination Committee of XVIVO Perfusion AB (publ) Proposes Emil Billbäck and Anne-Karen Hunt as New Members of the Board of Directors
accessnewswire.com
GEHC
JNJ
ABT
FNB Harvest d'actions à revenu élevé annonce les distributions de février 2026
businesswire.com
ELV
AMZN
MSFT
NVDA
MSTR
COIN
PLTR
TSLA
META
AMD
AVGO
GOOG
NFLX
AAPL
HOOD
RDDT
SOFI
BLKB
CRWD
JNJ
Harvest High Income Shares ETFs Announces February 2026 Distributions
businesswire.com
LLY
AMZN
MSFT
NVDA
COIN
PLTR
TSLA
META
AMD
AVGO
COST
GOOGL
NFLX
AAPL
CRWD
JNJ
ORCL
MSTR
Nicotine Gum Market Analysis Report 2026-2035: A $2.55 Billion Market by 2030 with Pfizer, GlaxoSmithKline, Haleon, Perrigo Co, and Johnson & Johnson Leading
globenewswire.com
PFE
GSK
JNJ
Tobacco Alternative Gums Analysis Report 2026-2035: A $4.25 Billion Market by 2030 with CVS Health, The Kroger Co., Walgreens Boots Alliance, along with Pfizer, Johnson & Johnson Leading
globenewswire.com
CVS
KR
PFE
JNJ
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
globenewswire.com
JNJ
ABBV
TMO
BDX
BAX
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
prnewswire.com
JNJ